Anixa Biosciences is a biotechnology company focused on using the body's immune system to diagnose, treat and prevent cancer. The company's subsidiary, Anixa Diagnostics Corporation, develops Cchek?, a platform for non-invasive blood tests for the early detection of cancer. The company's subsidiary, Certainty Therapeutics, Inc., develops immuno-therapy drugs against cancer. The company has focused on the development of a treatment for ovarian cancer. The company is also engaged in limited patent licensing activities in the area of encrypted audio/video conference calling.

County Bancorp is a bank holding company. Through its subsidiary, Investors Community Bank (the Bank), the company is engaged in providing banking and related business activities. The basic services provided by the Bank include: demand interest bearing and noninterest bearing accounts, money market deposit accounts, NOW accounts, mobile banking, internet banking, remote merchant deposit capture, banking by mail, and certain consumer loans. Deposits are accepted principally from within the company's primary market area through the provision of a variety of deposit instruments including checking accounts, money market accounts, savings accounts, term certificate accounts, and retirement savings plans.

Rhythm Pharmaceuticals is a biopharmaceutical company. The company's primary product candidate is setmelanotide, which is a melanocortin-4 (MC4) receptor agonist peptide for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The company is evaluating setmelanotide for the treatment of six single gene related MC4 pathway deficiencies: pro-opiomelanocortin (POMC), leptin receptor, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.